Lexicon Pharmaceuticals Inc

NASDAQ:LXRX 4:00:00 PM EDT

2.32

+0.01 (+0.43%)

4:32:02 PM EDT: $2.41 +0.09 (+3.88%)

Products

Lexicon Pharma Receives Fast Track Designation From The FDA For LX9211 For Diabetic Peripheral Neuropathic Pain

Published: 12/11/2020 13:33 GMT

Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for Lx9211 for Diabetic Peripheral Neuropathic Pain.
Lexicon Pharmaceuticals - Currently Enrolling Patients With Diabetic Peripheral Neuropathic Pain in a Phase 2 Proof-of-concept Study of Lx9211.
Lexicon Pharmaceuticals - Preparing to Initiate a Second Phase 2 Clinical Trial of Lx9211 in Post-herpetic Neuralgia.